Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer.
Pathol Res Pract
; 216(1): 152732, 2020 Jan.
Article
em En
| MEDLINE
| ID: mdl-31780055
ABSTRACT
BACKGROUND:
FK506 binding protein 9 (FKBP9) has been reported and identified for a long time, but its relationship with cancer is rarely studied. For example, the role of FK506 binding protein 9 in prostate cancer (PCa) is still unclear. Therefore, we decided to detect the expression level of FKBP9 in PCa and explore its clinical significance.METHODS:
The expression level of FKBP9 protein was detected by immunohistochemistry. In addition, it was demonstrated by high-throughput sequencing of mRNA levels in the TCGA (cancer genome atlas) dataset of 499 patients. Kaplan-meier analysis and Cox proportional hazard regression model were used to evaluate the relationship between FKBP9 expression and survival in prostate cancer patients.RESULTS:
The expression of FKBP9 was localized in the cytoplasm, which in normal prostate tissues was obviously lower than that in PCa tissues (Pâ¯=â¯0.001). High expression of FKBP9 was related with lymph node metastasis (Pâ¯=â¯0.022) and distant metastasis (Pâ¯=â¯0.028). Kaplan-Meier survival analysis revealed that the BCR-free survival of PCa patients with high FKBP9 level was significantly shortened (P=0.041).CONCLUSIONS:
FKBP9 may be a cancer promoter that enhances PCa progression, and the level of FKBP9 may be used as an independent precursor of PCa patients.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Próstata
/
Neoplasias da Próstata
/
Regulação Neoplásica da Expressão Gênica
/
Proteínas de Ligação a Tacrolimo
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Pathol Res Pract
Ano de publicação:
2020
Tipo de documento:
Article